Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (respiratory basal cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: doxycycline hyclate, cts-1027, rebimastat +2 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 4 Parkinson's papers of 7,549 | 0.79 |
| pathways Reactome | 5 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 3597
Sealed predictions
- MMP13 in dopamine neurons, braak-0.14 (p 0.716) → +0.16 (p 0.680)receipt 3605
Swarm cases
receipt 3605: MMP13 in dopamine neurons, braak
- power
- full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.00 (p 0.990, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.04 (p 0.874, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.14, sign flips 10; without severely affected donors +0.00 (p 0.990, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MMP13 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts